Accord BioPharma Launches IMULDOSA® at Unmatched Price for Patients Needing Treatment
Accord BioPharma Launches IMULDOSA® at Unmatched Price for Patients Needing Treatment
Accord BioPharma, a specialty division of Intas Pharmaceuticals, has officially announced the commercial launch of IMULDOSA® (ustekinumab-srlf), a biosimilar to STELARA® (ustekinumab). This new product arrives with a significant pricing advantage, being offered at the lowest wholesaler acquisition cost (WAC) among branded ustekinumab biosimilars. Notably, IMULDOSA is priced at a stunning 92% discount compared to STELARA, thereby enhancing accessibility for numerous patients in need of effective biologic therapies.
Patient-Centric Approach and Commitment to Accessibility
This launch serves not only as a commercial venture but also underscores Accord BioPharma’s commitment to patient-centric care. The launch is an integral component of the company's broader strategy to broaden patient access to targeted biologic therapies that have been pivotal in treating chronic, immune-mediated inflammatory conditions. With millions of Americans suffering from diseases like plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, the introduction of IMULDOSA provides a viable alternative to the high-cost treatments that have historically been prohibitive for many.
Accord BioPharma’s decision to implement a $0 co-pay program for eligible patients reflects its ongoing commitment to ensuring that financial barriers do not obstruct access to health care solutions. This initiative facilitates broader access to IMULDOSA, allowing more individuals living with these chronic conditions to receive important therapies that's proven to be effective.
Feedback Driven by Patient Advisory Board
In preparation for the launch, Accord BioPharma sought insights from its patient advisory board on the design of patient support materials. This feedback was crucial in creating resources that genuinely cater to patients’ needs, demonstrating Accord's dedication to understanding and addressing the experiences of those relying on these therapies.
A Robust Portfolio
Accord BioPharma's portfolio has shown remarkable growth, not only with the launch of IMULDOSA, but by also incorporating the UDENYCA® (pegfilgrastim-cbqv) franchise into its U.S. operations. Additionally, the company markets other critical biosimilars including HERCESSI™ (trastuzumab-strf) and CAMCEVI® (leuprolide) 42 mg injectable emulsion. As part of its commitment to innovation, Accord has partnered with Bio-Thera Solutions to introduce BAT2506, a proposed golimumab biosimilar, into the U.S. market, representing further expansion in Accord’s therapeutic pipeline.
A Vision for the Future
At the core of this initiative lies a visionary ethos: the belief that cost should never serve as a barrier to accessing essential health treatments. Chrys Kokino, Accord's U.S. President, articulated this sentiment, emphasizing the importance of delivering comprehensive solutions that significantly affect patients' lives. Accord BioPharma aims to lead the transformation of the biopharmaceutical landscape by not only providing alternatives but also by fostering a supportive ecosystem for clinicians and patients alike.
In the words of Binish Chudgar, Chairman of Intas Pharmaceuticals, “The launch of IMULDOSA in the United States represents our unwavering commitment to making high-quality, more cost-effective biologic therapies more accessible.” This launch is not just a milestone but a step towards reshaping treatment paradigms within immunologic care.
Conclusion
As the landscape of healthcare continues to evolve, innovations like IMULDOSA reflect Accord BioPharma’s leading position in enhancing patient access to vital therapies. With plans to continually expand their offerings, the company is poised to play a significant role in transforming the therapeutic options available to patients across the United States. For further information about IMULDOSA and other products, one can visit Accord BioPharma’s website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.